33P - Prognostic factors associated with lung cancer survival. A population-based study in the South of Spain

Date 15 April 2016
Event European Lung Cancer Conference 2016 (ELCC) 2016
Session Poster lunch
Topics Thoracic Malignancies
Presenter Isabel Linares
Citation Journal of Thoracic Oncology (2016) 11 (supplement 4): S57-S166. S1556-0864(16)X0004-4
Authors I. Linares1, J. Expósito2, J.P. Arrebola2, J. Sánchez-Cantalejo3, Y.L. Chang-Chan3, E. Molina3, R. Guerrero3, M.J. Sánchez3
  • 1Radiation Oncology, Hospital Universitario Virgen de las Nieves, 18014 - Granada/ES
  • 2Radiation Oncology, Hospital Universitario Virgen de las Nieves, Granada/ES
  • 3Instituto De Investigación Biosanitaria, Escuela Andaluza de Salud Pública, Granada/ES



Lung cancer is the leading cause of cancer death worldwide. The objective of this study was to analyze presentation, treatment and survival for lung cancer in Granada, and identify factors influencing survival.


Data were obtained from the population-based cancer registry located in Granada (Southern Spain). All cases with newly diagnosed primary lung cancer over the period 2011–2012 (n = 685) were included. Data regarding histology, stage, diagnostic tests, treatments and comorbidities was collected from clinical records. Two-year relative survival and relative excess risks of death were estimated.


65% of all cases were above 65 years age and 83% were men. A good performance status was present in 74%. Microscopic verification was obtained in 81% of cases. 81% were non-small cell lung cancer. Adenocarcinoma subtype (68.5%) and the age group 55–64 years were the most common among women. In men, squamous cancer (37%) and the age group >75 years were the most predominant. Overall, 16% of cases were stage I-II, 57% stage IV. 23% of cases were operated. Radiotherapy and chemotherapy were administered in 28% and 45% of cases respectively. Two-year survival was 18%; 67% for stage I, 5% for stage IV. Survival was higher among women: 29% versus 16% (men: reference); 75 years: reference); and good performance status: 23% versus 1.8% (bad performance status: reference). Cases in which a microscopic verification was obtained and those undergoing surgery had higher survival: 69% versus 9.2% in cases operated. In multivariate analysis, bad performance status, smoker, advanced stage and non surgical treatment were significant independent negative prognostic factors.


Performance status, stage and surgery are the main factors affecting survival. Focusing efforts on early diagnosis of lung cancer may improve treatment options and thus modify the results.

Clinical trial identification

There is no trial protocol number

Legal entity responsible for the study

María José Sánchez


Escuela Andaluza de Salud Pública. Hospital Universitario Virgen de las Nieves


All authors have declared no conflicts of interest.